Plotted by close date where disclosed, otherwise announcement. Select any marker to jump to the deal entry.
Three patterns run through 908 Devices's acquisitions — what it looks for, how it pays, and how it folds in what it buys.
1 acquisitions — each with the deal value, financing structure, target revenue, and executive commentary where disclosed.
RedWave Technology (legally CAM2 Technologies, LLC, a Connecticut LLC doing business as RedWave Technology) is a provider of portable FTIR (Fourier Transform Infrared) spectroscopic analyzers for rapid chemical identification of bulk materials. Founded in 2016 and based in Danbury, Connecticut with 39 employees, RedWave had placed more than 700 portable analyzers with customers in more than 20 countries. The acquisition added optical spectroscopy to 908 Devices' handheld platform for forensic workflows that detect and identify unknown solids, liquids, vapors and aerosols at the point of need, and brought a line of accessories to 908 Devices' desktop portfolio for pharma Process Analytical Technology (PAT) and industrial QC. $53.5 million initial consideration ($45.0 million cash plus 1,497,171 shares of common stock valued at approximately $8.5 million on the day before closing), with up to 4,000,000 additional contingent 'earnout' shares (valued at up to approximately $22.7 million at signing) tied to RedWave-product revenue over the two years to April 30, 2026.
We're thrilled to welcome the RedWave team to 908 Devices. Our technology platforms are complementary as our forensics customers rely on both mass spec and FTIR analyzers to rapidly assess and monitor their environment for dangerous trace chemicals and bulk chemical hazards. RedWave Technology is a high growth and profitable company with innovative products that can immediately leverage our sales channel. RedWave is a strong fit and enables us to accelerate our strategic objectives.Kevin J. Knopp — CEO and Co-founder, 908 Devices
RedWave Technology and 908 Devices share an extraordinary passion for innovation and customer care. Together, we can accelerate the development of new products and services that provide first responders with best-in-class chemical identification tools that enable them to fulfill their mission of keeping our communities safe.Jon Frattaroli — CEO of RedWave Technology, now VP, Strategy at 908 Devices
Up to 4,000,000 unregistered earnout shares may be issued based on RedWave-product 'Earnout Revenue': at least 1,000,000 shares if Earnout Revenue reaches $37 million, scaling to the 4,000,000-share maximum at $45 million or more; no earnout shares below the threshold. Approximately $4.5 million of the cash consideration was placed in a 12-month indemnification escrow.